Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diagnostic Efficacy of 68Ga-SFB6-ZN01 PET/CT in Malignant Tumors
NCT07420036Phase 1Not yet recruiting
- Sponsor
- Zhongnan Hospital of Wuhan University
- Start
- Mar 2026
- Primary completion
- Dec 2028
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga-SFB6-ZN01 in malignant solid tumor, sponsored by Zhongnan Hospital of Wuhan University. Primary endpoint: Diagnostic Efficacy of 68Ga-SFB6-ZN01 PET/CT. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
68Ga-SFB6-ZN01
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT07420036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07420036.